The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Cancer Monoclonal Antibodies-Global Market Insights and Sales Trends 2024

Cancer Monoclonal Antibodies-Global Market Insights and Sales Trends 2024

Publishing Date : Dec, 2023

License Type :
 

Report Code : 1855403

No of Pages : 74

Ask Your Query

Synopsis

The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.

The global Cancer Monoclonal Antibodies market size is expected to reach US$ 63810 million by 2029, growing at a CAGR of 9.2% from 2023 to 2029. The market is mainly driven by the significant applications of Cancer Monoclonal Antibodies in various end use industries. The expanding demands from the Liver, Breast, Blood and Brain, are propelling Cancer Monoclonal Antibodies market. Murine Antibodies, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Chimeric and Humanised Antibodies segment is estimated at % CAGR for the next seven-year period.

Cancer is one of the leading causes of death globally. There were 10.9 million new cases, in 2002, which increased to 14.1 million, in 2012 (approximately 30% growth in a decade). The WHO expects this number to increase by 70%, over the next two decades. According to the WHO, almost 70% of deaths occur in low and middle-income countries. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns.

Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.

Report Objectives

This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Cancer Monoclonal Antibodies, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:

This report provides in-depth analysis of the global Cancer Monoclonal Antibodies market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.

This report profiles key players in the global Cancer Monoclonal Antibodies market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Cancer Monoclonal Antibodies sales data, market share and ranking.

This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.

This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.

Key companies of Cancer Monoclonal Antibodies covered in this report include F. Hoffmann-La Roche, Amgen, Bristol-Myers Squibb and Takeda Pharmaceuticals, etc.

The global Cancer Monoclonal Antibodies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

Market Segmentation

Company Profiles:

  • F. Hoffmann-La Roche
  • Amgen
  • Bristol-Myers Squibb
  • Takeda Pharmaceuticals

Global Cancer Monoclonal Antibodies market, by region:

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, UK, Italy, etc.)
  • Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
  • South America (Brazil, etc.)
  • Middle East and Africa (Turkey, GCC Countries, Africa, etc.)

Global Cancer Monoclonal Antibodies market, Segment by Type:

  • Murine Antibodies
  • Chimeric and Humanised Antibodies
  • Fully Humanized Antibodies
  • Others

Global Cancer Monoclonal Antibodies market, by Application:

  • Liver
  • Breast
  • Blood
  • Brain
  • Hodgkins and Non-Hodgkins lymphoma
  • Colorectal
  • Leukaemia
  • Others

Core Chapters

Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Cancer Monoclonal Antibodies manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Cancer Monoclonal Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.

Index

1 Cancer Monoclonal Antibodies Market Overview
1.1 Cancer Monoclonal Antibodies Product Overview
1.2 Cancer Monoclonal Antibodies Market Segment by Type
1.2.1 Murine Antibodies
1.2.2 Chimeric and Humanised Antibodies
1.2.3 Fully Humanized Antibodies
1.2.4 Others
1.3 Global Cancer Monoclonal Antibodies Market Size by Type
1.3.1 Global Cancer Monoclonal Antibodies Market Size Overview by Type (2018-2029)
1.3.2 Global Cancer Monoclonal Antibodies Historic Market Size Review by Type (2018-2023)
1.3.3 Global Cancer Monoclonal Antibodies Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Cancer Monoclonal Antibodies Sales Breakdown by Type (2018-2023)
1.4.2 Europe Cancer Monoclonal Antibodies Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Cancer Monoclonal Antibodies Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Cancer Monoclonal Antibodies Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Cancer Monoclonal Antibodies Sales Breakdown by Type (2018-2023)
2 Global Cancer Monoclonal Antibodies Market Competition by Company
2.1 Global Top Players by Cancer Monoclonal Antibodies Sales (2018-2023)
2.2 Global Top Players by Cancer Monoclonal Antibodies Revenue (2018-2023)
2.3 Global Top Players by Cancer Monoclonal Antibodies Price (2018-2023)
2.4 Global Top Manufacturers Cancer Monoclonal Antibodies Manufacturing Base Distribution, Sales Area, Product Type
2.5 Cancer Monoclonal Antibodies Market Competitive Situation and Trends
2.5.1 Cancer Monoclonal Antibodies Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Cancer Monoclonal Antibodies Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Cancer Monoclonal Antibodies as of 2022)
2.7 Date of Key Manufacturers Enter into Cancer Monoclonal Antibodies Market
2.8 Key Manufacturers Cancer Monoclonal Antibodies Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Cancer Monoclonal Antibodies Status and Outlook by Region
3.1 Global Cancer Monoclonal Antibodies Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Cancer Monoclonal Antibodies Historic Market Size by Region
3.2.1 Global Cancer Monoclonal Antibodies Sales in Volume by Region (2018-2023)
3.2.2 Global Cancer Monoclonal Antibodies Sales in Value by Region (2018-2023)
3.2.3 Global Cancer Monoclonal Antibodies Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Cancer Monoclonal Antibodies Forecasted Market Size by Region
3.3.1 Global Cancer Monoclonal Antibodies Sales in Volume by Region (2024-2029)
3.3.2 Global Cancer Monoclonal Antibodies Sales in Value by Region (2024-2029)
3.3.3 Global Cancer Monoclonal Antibodies Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Cancer Monoclonal Antibodies by Application
4.1 Cancer Monoclonal Antibodies Market Segment by Application
4.1.1 Liver
4.1.2 Breast
4.1.3 Blood
4.1.4 Brain
4.1.5 Hodgkins and Non-Hodgkins lymphoma
4.1.6 Colorectal
4.1.7 Leukaemia
4.1.8 Others
4.2 Global Cancer Monoclonal Antibodies Market Size by Application
4.2.1 Global Cancer Monoclonal Antibodies Market Size Overview by Application (2018-2029)
4.2.2 Global Cancer Monoclonal Antibodies Historic Market Size Review by Application (2018-2023)
4.2.3 Global Cancer Monoclonal Antibodies Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Cancer Monoclonal Antibodies Sales Breakdown by Application (2018-2023)
4.3.2 Europe Cancer Monoclonal Antibodies Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Cancer Monoclonal Antibodies Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Cancer Monoclonal Antibodies Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Cancer Monoclonal Antibodies Sales Breakdown by Application (2018-2023)
5 North America Cancer Monoclonal Antibodies by Country
5.1 North America Cancer Monoclonal Antibodies Historic Market Size by Country
5.1.1 North America Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Cancer Monoclonal Antibodies Sales in Volume by Country (2018-2023)
5.1.3 North America Cancer Monoclonal Antibodies Sales in Value by Country (2018-2023)
5.2 North America Cancer Monoclonal Antibodies Forecasted Market Size by Country
5.2.1 North America Cancer Monoclonal Antibodies Sales in Volume by Country (2024-2029)
5.2.2 North America Cancer Monoclonal Antibodies Sales in Value by Country (2024-2029)
6 Europe Cancer Monoclonal Antibodies by Country
6.1 Europe Cancer Monoclonal Antibodies Historic Market Size by Country
6.1.1 Europe Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Cancer Monoclonal Antibodies Sales in Volume by Country (2018-2023)
6.1.3 Europe Cancer Monoclonal Antibodies Sales in Value by Country (2018-2023)
6.2 Europe Cancer Monoclonal Antibodies Forecasted Market Size by Country
6.2.1 Europe Cancer Monoclonal Antibodies Sales in Volume by Country (2024-2029)
6.2.2 Europe Cancer Monoclonal Antibodies Sales in Value by Country (2024-2029)
7 Asia-Pacific Cancer Monoclonal Antibodies by Region
7.1 Asia-Pacific Cancer Monoclonal Antibodies Historic Market Size by Region
7.1.1 Asia-Pacific Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Cancer Monoclonal Antibodies Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Cancer Monoclonal Antibodies Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Cancer Monoclonal Antibodies Forecasted Market Size by Region
7.2.1 Asia-Pacific Cancer Monoclonal Antibodies Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Cancer Monoclonal Antibodies Sales in Value by Region (2024-2029)
8 Latin America Cancer Monoclonal Antibodies by Country
8.1 Latin America Cancer Monoclonal Antibodies Historic Market Size by Country
8.1.1 Latin America Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Cancer Monoclonal Antibodies Sales in Volume by Country (2018-2023)
8.1.3 Latin America Cancer Monoclonal Antibodies Sales in Value by Country (2018-2023)
8.2 Latin America Cancer Monoclonal Antibodies Forecasted Market Size by Country
8.2.1 Latin America Cancer Monoclonal Antibodies Sales in Volume by Country (2024-2029)
8.2.2 Latin America Cancer Monoclonal Antibodies Sales in Value by Country (2024-2029)
9 Middle East and Africa Cancer Monoclonal Antibodies by Country
9.1 Middle East and Africa Cancer Monoclonal Antibodies Historic Market Size by Country
9.1.1 Middle East and Africa Cancer Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Cancer Monoclonal Antibodies Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Cancer Monoclonal Antibodies Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Cancer Monoclonal Antibodies Forecasted Market Size by Country
9.2.1 Middle East and Africa Cancer Monoclonal Antibodies Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Cancer Monoclonal Antibodies Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 F. Hoffmann-La Roche
10.1.1 F. Hoffmann-La Roche Company Information
10.1.2 F. Hoffmann-La Roche Introduction and Business Overview
10.1.3 F. Hoffmann-La Roche Cancer Monoclonal Antibodies Sales, Revenue and Gross Margin (2018-2023)
10.1.4 F. Hoffmann-La Roche Cancer Monoclonal Antibodies Products Offered
10.1.5 F. Hoffmann-La Roche Recent Development
10.2 Amgen
10.2.1 Amgen Company Information
10.2.2 Amgen Introduction and Business Overview
10.2.3 Amgen Cancer Monoclonal Antibodies Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Amgen Cancer Monoclonal Antibodies Products Offered
10.2.5 Amgen Recent Development
10.3 Bristol-Myers Squibb
10.3.1 Bristol-Myers Squibb Company Information
10.3.2 Bristol-Myers Squibb Introduction and Business Overview
10.3.3 Bristol-Myers Squibb Cancer Monoclonal Antibodies Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Bristol-Myers Squibb Cancer Monoclonal Antibodies Products Offered
10.3.5 Bristol-Myers Squibb Recent Development
10.4 Takeda Pharmaceuticals
10.4.1 Takeda Pharmaceuticals Company Information
10.4.2 Takeda Pharmaceuticals Introduction and Business Overview
10.4.3 Takeda Pharmaceuticals Cancer Monoclonal Antibodies Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Takeda Pharmaceuticals Cancer Monoclonal Antibodies Products Offered
10.4.5 Takeda Pharmaceuticals Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Cancer Monoclonal Antibodies Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Cancer Monoclonal Antibodies Industrial Chain Analysis
11.4 Cancer Monoclonal Antibodies Market Dynamics
11.4.1 Cancer Monoclonal Antibodies Industry Trends
11.4.2 Cancer Monoclonal Antibodies Market Drivers
11.4.3 Cancer Monoclonal Antibodies Market Challenges
11.4.4 Cancer Monoclonal Antibodies Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Cancer Monoclonal Antibodies Distributors
12.3 Cancer Monoclonal Antibodies Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock